title: Long-term Outcomes of Medical Therapy Versus Coronary Revascularisation in Patients with Intermediate Stenoses Guided by Pressure Wire.
abstract: BACKGROUND
  This study aimed to examine the long-term clinical outcomes of coronary fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) in a real-world population in an Asian tertiary centre.
  
  
  METHODS
  All patients who underwent FFR measurement for intermediate coronary lesions in our centre from June 2002 to December 2009 were enrolled. A threshold of FFR ≤0.75 was used for revascularisation. All the patients were prospectively followed-up for major adverse cardiac events (MACE) of death, myocardial infarction (MI), target vessel revascularisation (TVR) and stent thrombosis.
  
  
  RESULTS
  Based on FFR measurement, 368 (57%) patients were treated medically while 278 (43%) underwent revascularisation. At a mean follow-up duration of 29.7 ± 16 months, 53 (14.4%) patients in the medical therapy group and 32 (11.5%) patients in the revascularised group experienced MACE (P = 0.282). There were no statistical differences in all the clinical endpoints between the 2 groups.
  
  
  CONCLUSIONS
  Medical therapy based on FFR measurement is associated with low incidences of MACE at long-term follow-up.
authors.affiliation: Department of Cardiology, Shanghai Chest Hospital, People's Republic of China.
authors.forename: Hongyu
authors.initials: H
authors.lastname: Shi
authors.forename: Chi Hang
authors.initials: CH
authors.lastname: Lee
authors.forename: Mark Y Y
authors.initials: MY
authors.lastname: Chan
authors.forename: Adrian F
authors.initials: AF
authors.lastname: Low
authors.forename: Swee Guan
authors.initials: SG
authors.lastname: Teo
authors.forename: Koo Hui
authors.initials: KH
authors.lastname: Chan
authors.forename: Rishi
authors.initials: R
authors.lastname: Sethi
authors.forename: Arthur Mark
authors.initials: AM
authors.lastname: Richards
authors.forename: Huay Cheem
authors.initials: HC
authors.lastname: Tan
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D023921:Coronary Stenosis / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin